We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02024529
Recruitment Status : Completed
First Posted : December 31, 2013
Results First Posted : August 9, 2022
Last Update Posted : August 9, 2022
Sponsor:
Information provided by (Responsible Party):
Ampio Pharmaceuticals. Inc.

Brief Summary:
This study will evaluate the efficacy of an Intra-Articular Injection of Ampion™ in Adults with pain due to osteoarthritis of the knee.

Condition or disease Intervention/treatment Phase
Osteoarthritis of the Knee Biological: 4 mL injection of Ampion Drug: 4 mL Injection of Placebo Phase 3

Detailed Description:

A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion™ in Adults with pain due to osteoarthritis of the knee.

The primary study objective was to evaluate the efficacy of 4 mL Ampion versus 4 mL saline intra-articular (IA) injection in treating knee pain when administered to subjects suffering from osteoarthritis (OA) of the knee (OAK).

The secondary study objectives included evaluation of the safety of an IA injection of Ampion vs saline, efficacy of IA injection of Ampion vs saline in improving knee function.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 538 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of a Single Intra-articular Injection of Ampion in Adults With Pain Due to Osteoarthritis (OA) of the Knee
Actual Study Start Date : January 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: AMPION™ 4 mL dose
4 mL injection of Ampion
Biological: 4 mL injection of Ampion
4 mL injection of Ampion

Placebo Comparator: Placebo 4 mL dose
4 mL injection of placebo
Drug: 4 mL Injection of Placebo
4 mL Injection of Placebo
Other Name: Saline




Primary Outcome Measures :
  1. Change in WOMAC A Pain [ Time Frame: Scored at Baseline and 12 weeks ]
    Mean Change in WOMAC A Pain (Western Ontario and McMaster Universities Arthritis Index) score from Baseline to 12 weeks. 5-point Likert scale (0=none to 4=extreme). A negative difference constitutes a decrease in pain with a greater negative value indicating a greater reduction in pain.


Secondary Outcome Measures :
  1. Change in WOMAC C Function [ Time Frame: Scored at Baseline and 12 weeks. ]
    Mean change in WOMAC C function score (Western Ontario and McMaster Universities Arthritis Index) from Baseline to 12 weeks. 5-point Likert scale indicating limitation of function (0=none to 4=extreme). A greater negative value indicates a improvement in function.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, 35 years to 85 years old (inclusive) who are ambulatory but suffering from moderate to moderately severe pain from osteoarthritis in the index knee as evidenced by a rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale at screening.
  2. Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (Kellgren Lawrence Grade II, III, IV). Confirmatory x-ray must be taken at Screening and assessed using Kellgren Lawrence grading system.
  3. Moderate to moderately-severe OA pain in the index knee even with dosing of nonsteroidal anti-inflammatory drug (NSAID) in the 4 weeks prior to screening.
  4. No analgesia (including acetaminophen [paracetamol]) taken 12 hours prior to an efficacy measure; and,
  5. Able to provide written informed consent to participate in the study.
  6. Willing and able to comply with all study requirements and instructions of the site study staff.

Exclusion Criteria:

  1. Previous participation in an Ampion™ study.
  2. Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the principal investigator.
  3. Isolated patella femoral syndrome, also known as chondromalacia.
  4. Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (e.g., cancer, congenital defects, spine OA).
  5. Major injury to the index knee within the 12 months prior to screening.
  6. Severe hip OA ipsilateral to the index knee.
  7. Presence of tense effusions.
  8. Any pain that could interfere with the assessment of index knee pain (e.g., pain in any other part of the lower extremities, pain radiating to the knee).
  9. Initiation or change in any pharmacological or non-pharmacological treatment for OA during the 4 weeks prior to randomization or likely to be changed during the duration of the study.
  10. Use of the following medications anticipated to be required during the study:

    • Intra-articular pain medications in the study knee
    • Analgesics containing opioids. (NSAIDs may be continued at levels preceding the study and acetaminophen is available as a rescue medication during the study from the provided supply.)
    • Topical treatment on osteoarthritis index knee needed during the study
    • Use of significant anticoagulant therapy, oral or injectable, during the study (aspirin and clopidogrel are allowed)
    • Systemic treatments that may interfere with safety or efficacy assessments during the study such as immunosuppressants
  11. Use of corticosteroids >10 mg prednisolone equivalent per day (if ≤10 mg prednisolone, the dose must be stable).
  12. Use of human albumin treatment in the 3 months before randomization.
  13. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion).
  14. A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate).
  15. Principal Investigator considers the patient unfit for the study based on medical review and screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02024529


Sponsors and Collaborators
Ampio Pharmaceuticals. Inc.
Investigators
Layout table for investigator information
Study Director: Howard Levy, MD Ampio Pharmaceuticals. Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: Ampio Pharmaceuticals. Inc.
ClinicalTrials.gov Identifier: NCT02024529    
Other Study ID Numbers: AP-004-A
First Posted: December 31, 2013    Key Record Dates
Results First Posted: August 9, 2022
Last Update Posted: August 9, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ampio Pharmaceuticals. Inc.:
Osteoarthritis
osteoarthritis of the knee
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases